Long-term safety study of a new ALS treatment in experienced patients

Plain-English translation of NCT07571200 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated September 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is a follow-up study for people with ALS who have already participated in an earlier clinical trial. Participants will continue receiving , an experimental medication given by injection into the spinal fluid, to see how well it is tolerated over a long period of time. The main goal is to gather information about safety and how the body responds to ongoing treatment.

ALS is a serious condition that gradually weakens muscles over time, and current treatment options are limited. By following patients who have already tried this medication in an earlier study, researchers can learn whether this treatment can be safely given for extended periods and whether it might help slow disease progression.

Do you qualify?

You likely qualify if…

you have completed a previous ALS research study and finished its full treatment and follow-up phases
you are willing to continue receiving injections of the study medication into your spinal fluid
you do not have safety concerns or disease changes from the earlier study that would make continued treatment risky

You likely don't qualify if…

you had to stop taking the study medication during the earlier trial because it was unsafe
your ALS progressed severely during the parent study, such as requiring permanent mechanical ventilation
you developed a serious, unresolved side effect or new medical illness during the earlier study that makes participation unsafe

What participation looks like

If you join, you will continue receiving injections of the medication directly into your spinal fluid as part of this long-term follow-up study, which lasts at least 96 weeks (about 2 years). You will have regular study visits where doctors will monitor your safety, check how you are doing, and watch for any changes in your symptoms. The study is designed to gather detailed information about whether the treatment is safe and tolerable when used over an extended period in people with ALS.

AI-generated summary from trial data · Sep 3, 2026 · Not medical advice

Trial locations(10 sites)

Belgium

UZ Leuven, Leuven

Canada

University Hospital - London Health Sciences Centre, London

McGill University Health Centre, Montreal

Sunnybrook Research Institute, Toronto

Germany

Universitätsklinikum Schleswig-Holstein, Lübeck